## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Proposed Single Technology Appraisal (STA)**

# Naltrexone-bupropion (prolonged release) for treating obesity and overweight

# Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Orexigen Therapeutics (bupropion,	Allied Health Professionals Federation
naltrexone)	<ul> <li>Board of Community Health Councils in Wales</li> </ul>
Patient/carer groups	British Cardiovascular Industry
Afiya Trust	Association
Beat	British National Formulary
<ul> <li>BEMDA: Black and Ethnic Minority</li> </ul>	<ul> <li>Care Quality Commission</li> </ul>
Diabetes Association	<ul> <li>Commissioning Support Appraisals</li> </ul>
Black Health Agency	Services
Blood Pressure UK	<ul> <li>Department of Health, Social Services</li> </ul>
British Cardiac Patients Association	and Public Safety for Northern Ireland
British Obesity Society	Diabetes UK Cymru
Cardiovascular Care Partnership UK	Healthcare Improvement Scotland
Diabetes Research & Wellness	Medicines and Healthcare products
Foundation	Regulatory Agency
Diabetes UK	National Association of Primary Care
Equalities National Council	National Pharmacy Association
HEART UK     HOOD HIK	NHS Alliance     NHS Corresponded Madiaire and Unit
HOOP UK     In Dependent Dishetes Trust	NHS Commercial Medicines Unit     NHS Confederation
InDependent Diabetes Trust     Industry Thorses	<ul><li>NHS Confederation</li><li>Scottish Medicines Consortium</li></ul>
INsulin Pump Therapy     Insulin Pumpors	Scottish Medicines Consortium
<ul><li>Insulin Pumpers</li><li>Muslim Council of Great Britain</li></ul>	Possible comparator manufacturers
<ul> <li>Muslim Council of Great Britain</li> <li>Muslim Health Network</li> </ul>	Actavis (orlistat)
National Obesity Forum	GlaxoSmithKline (orlistat)
Network of Sikh Organisations	Roche (orlistat)
Overeaters Anonymous	Teva UK (orlistat)
South Asian Health Foundation	Tota or (ornotat)
Specialised Healthcare Alliance	Relevant research groups
Surya Foundation	British Society for Cardiovascular
Weight Concern	Research
- Troight Concom	Cochrane Heart Group
Professional groups	Cochrane Metabolic & Endocrine
Association for the Study of Obesity	Disorders Group
Association of British Clinical	Cochrane Peripheral Vascular Disease
Diabetologists	Group

National Institute for Health and Care Excellence

Provisional matrix for the technology appraisal of naltrexone-bupropion (prolonged release) for treating obesity and overweight

Issue date: March 2014

#### Consultees Commentators (no right to submit or appeal) • Cochrane Public Health Group British Association for Nursing in Cardiac Care CORDA British Cardiovascular Intervention Health Research Authority Society • MRC Clinical Trials Unit **British Cardiovascular Society** National Institute for Health Research **British Dietetic Association** Research Institute for the Care of Older **British Geriatrics Society** People **British Heart Foundation** • Wellcome Trust **British Hypertension Society British Nutrition Foundation Evidence Review Group** Evidence Review Group tbc **Diabetes Specialist Nurses** National Institute for Health Research Dieticians in Obesity Management Health Technology Assessment Faculty of Public Health Medicine Programme National Centre for Eating Disorders National Diabetes Nurse Consultant Associated Guideline Groups Group National Clinical Guidelines Centre National Heart Forum UK Primary Care Cardiovascular Society Associated Public Health Groups **Primary Care Diabetes Society** Public Health England Royal College of General Public Health Wales NHS Trust **Practitioners** Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Cardiological Science & **Technology** Society for Endocrinology Society for Vascular Technology Society of Vascular Nurses The Nutrition Society The Obesity Management Association United Kingdom Clinical Pharmacy Association Vascular Society Others Department of Health NHS Bath and North East Somerset CCG NHS Fylde and Wyre CCG NHS England Welsh Government

National Institute for Health and Care Excellence

Provisional matrix for the technology appraisal of naltrexone-bupropion (prolonged release) for treating obesity and overweight

Issue date: March 2014

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

### **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

Issue date: March 2014

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.